Voyager Therapeutics公司宣布，其候选药物Vy1706在为期六个月的GLP（良好实验室规范）毒理学研究中，单次静脉注射剂量表现出良好的耐受性，并成功降低了Tau蛋白水平。这一积极结果为该药物后续的临床开发奠定了重要基础。公司计划于2026年下半年启动针对阿尔茨海默病的临床试验。
这项长期毒理学研究的数据至关重要，它验证了Vy1706在非临床环境下的安全性与潜在疗效。Tau蛋白的病理聚集是阿尔茨海默病等神经退行性疾病的关键标志之一，因此，观察到Tau蛋白的减少被视为一个极具前景的药理学信号。该研究的顺利完成，扫清了Vy1706迈向人体临床试验的关键障碍。
随着全球阿尔茨海默病患者群体持续扩大，市场对创新疗法需求迫切。Voyager Therapeutics此番进展，不仅推进了其自身研发管线，也为该疾病领域的治疗探索提供了新的可能性。公司预计在2026年下半年正式启动相关临床试验，进一步评估Vy1706在患者中的安全性与有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.